When fused with FER, MAN2A1 transforms into an oncogene; around 80% of prostate cancer patients with MAN2A1-FER have exhibited a dismal clinical prognosis according to earlier studies [38]. This evidence concerns the gene MAN2A1 and prostate carcinoma.